The impact of innovative glucose-lowering drugs on the course and outcome of COVID-19 in patients with type 2 diabetes mellitus
Patients with type 2 diabetes mellitus (T2DM) are at high risk of adverse outcomes in coronavirus infection (COVID-19). Despite the gradual resolution of the pandemic, new strains of the virus are emerging, characterized by high contagiousness, and the risk of infection becoming a seasonal disease i...
Saved in:
| Main Authors: | T. N. Markova, M. S. Stas |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2024-05-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/13106 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Novel glucose-lowering agents that benefit diabetic foot: icing on the cake
by: Qin Li, et al.
Published: (2025-07-01) -
Comparison of New‐Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium–Glucose Cotransporter‐2 Inhibitors, Dipeptidyl Peptidase‐4 Inhibitors, or Glucagon‐Like Peptide‐1 Agonists: A Population‐Based Cohort Study
by: Oscar Hou‐In Chou, et al.
Published: (2025-06-01) -
The advisory board resolution on the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes
by: M. B. Antsiferov, et al.
Published: (2023-05-01) -
Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence
by: Jian‐Yu Jhu, et al.
Published: (2025-02-01) -
Systematic Review of Cardiovascular Outcomes with Sulfonylureas, GLP-1 RA, and DPP-4 Inhibitors in Type 2 Diabetes Mellitus
by: Koo Thai Hau, et al.
Published: (2024-07-01)